Promore Pharma AB entered into voluntary liquidation in accordance with a decision made at a general meeting on October 5, 2023.

In the spring, the company received the final results of the PHSU05 clinical trial, which showed that the treatment effect of ensereptide was insufficient to justify further investments, which is why the board later decided to discontinue this development project. This resulted in a sharp decline in the company’s market capitalization. In addition, financial markets have been unstable. Overall, this has created a very challenging climate for the company to conduct public share issues, which would be needed to finance the continued development of the company’s main remaining asset, the drug candidate ropocamptide.

“It should be emphasized that management and the Board of Directors believe that there are conditions for carrying out a reverse acquisition or some other form of structural transaction during the liquidation,” said Jonas Ekblom, acting CEO. “If a final agreement is consummated, the liquidator may propose to the general meeting that the liquidation should cease, and the business recommence. It may also be appropriate to carry out a distribution of the shares in the company’s wholly owned subsidiary Pergasus AB, where the patent rights for ropocamptide have been collected, to Promore Pharma’s shareholders.”

The board has, together with external advisors, explored several financing options as well as opportunities for various forms of strategic transactions.

Negotiations regarding possible structural transactions are ongoing and two letters of intent have been signed regarding concrete business proposals, but no binding agreements have been signed.

The board therefore considers that there is currently no acceptable alternative to a decision on voluntary liquidation, in order to avoid a bankruptcy situation in the event that a structural transaction could not be implemented.